Cancer and leukemia group B breast committee: decades of progress and plans for the future.
The Breast Committee of the Cancer and Leukemia Group B was formed in 1969 under the direction of James Holland. Initial studies examined combination chemotherapy for advanced disease. Although the committee has continued to conduct studies in patients with advanced disease, adjuvant therapy has been an even more important focus for the past 30 years. Over the past 20 years, studies have focused on optimization of chemotherapy through the testing of dose and schedule, the value of adding novel agents, and the role of biological agents. Current and future projects are aimed at exploiting and increasing our growing knowledge of the molecular biology of breast cancer by developing targeted therapies.
Hudis
Clifford A
CA
Memorial Sloan-Kettering Cancer Center, New York, New York and Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Winer
Eric P
EP
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D049673:History, 20th Century; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008495:Medical Oncology / Q000266:history / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy; D012955:Societies, Medical
D000970:Antineoplastic Agents